Previous close | 34.39 |
Open | 34.10 |
Bid | 34.42 x 200 |
Ask | 34.50 x 100 |
Day's range | 34.10 - 34.48 |
52-week range | 14.31 - 39.79 |
Volume | |
Avg. volume | 453,826 |
Market cap | 1.632B |
Beta (5Y monthly) | 2.88 |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
Inhibrx, Inc. (INBX) delivered earnings and revenue surprises of -61.68% and 1,534%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
J&J (JNJ) beats estimates for fourth-quarter earnings and sales. Sanofi (SNY) is set to acquire Inhibrx's (INBX) rare disease pipeline candidate, INBRX-101.
Gilead Sciences (GILD) and Inhibrx (INBX) are in the spotlight on regulatory and pipeline updates.